PubRank

Patricia Maiso

Author PubWeight™ 30.15‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012 2.35
2 BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013 2.34
3 P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood 2011 1.77
4 Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 2010 1.71
5 Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2005 1.66
6 Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol 2011 1.66
7 LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood 2012 1.42
8 New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008 1.41
9 Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2009 1.40
10 In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2009 1.38
11 Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 2008 1.17
12 The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica 2008 1.13
13 microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood 2010 1.11
14 Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res 2008 1.11
15 Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clin Cancer Res 2011 0.97
16 Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia. Clin Cancer Res 2011 0.90
17 FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res 2011 0.90
18 Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. J Hematol Oncol 2010 0.84
19 Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma. PLoS One 2013 0.82
20 microRNA aberrations in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013 0.78
21 Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica 2011 0.78
22 Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. Clin Cancer Res 2012 0.78
23 Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma. Ann Hematol 2011 0.77
24 Targeting the bone marrow in Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011 0.76
25 The bone marrow microenvironment in waldenstrom macroglobulinemia. Ther Adv Hematol 2011 0.75
26 Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis. Clin Lymphoma Myeloma Leuk 2011 0.75
27 The bone marrow niche in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011 0.75